Regeneron Pharmaceuticals, Inc. (REGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit
On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea
Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 ...
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts- Hagens Berman
Regeneron is also embroiled in a securities fraud class action lawsuit stemming from a significant stock price drop on October 31, 2024. Shares plunged $84.59 that day, wiping out approximately $9 ...
MarketWatch11d
Regeneron Gets New FDA Review of Linvoseltamab for Multiple Myeloma
Regeneron Pharmaceuticals said the Food and Drug Administration has accepted its resubmitted application seeking approval of linvoseltamab for certain patients with the blood cancer multiple ...